In vitro activity of piperacillin/tazobactam against isolates from patients enrolled in clinical trials

International Journal of Antimicrobial Agents

Volumn 7, Issue 1, 1996, Pages 15-21

  Kuck, Nydia A ^a   Jacobus, Nilda V ^a   Spengler, Michael D ^a   Testa, Raymond T ^a  

^a WYETH RESEARCH   (United States)

Author keywords

In vitro susceptibility; Piperacillin tazobactam

Indexed keywords

CEFTAZIDIME; CLINDAMYCIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TICARCILLIN; TIMENTIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROCOCCUS; HAEMOPHILUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 0030012681     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-8579(96)00004-0     Document Type: Article

References (26)

1. Arnoff SC, Jacobs MR, Johenning SC, Yamabe S. Comparative activities of the β-lactamase inhibitors YTR-830, sodium clavulanate and sulbactam combined with amoxacillin or ampicillin. Antimicrob Agents Chemother 1984;26:580-582.
2. Jacobs MR, Arnoff SC, Johenning S, Shlaes DM, Yamaba S. Comparative activities of the β-lactamases inhibitors YTR-830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined β-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother 1986; 29:980-985.
3. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 1993;37:851-858.
4. Appelbaum PC, Jacobs MR, Spangler SK, Yamobe S. Comparative activity of β-lactamase inhibitor YTR-830, clavulanate and sulbactam combined with β-lactams against β-lactamase producing anaerobes. Antimicrob Agents Chemother 1986;30:789-791.
5. Fass RJ, Prior RB. Comparative in vitro activities of piperacillin/tazobactam and ticarcillin/clavulanate. Antimicrob Agents Chemother 1989;33:1268-1274.
6. Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT. Comparative in vitro and in vivo activities of piperacillin combined with β-lactamase inhibitors tazobactam, clavulanic acid and sulbactam. Antimicrob Agents Chemother 1989;33:1964-1969.
7. D'Amato RF, Bottone FJ, Amsterdam D. Substrate profile systems for the identification of bacteria and yeasts by rapid and automated approaches. In: Balows A, Hausler WJ, Hermmann KL, Isenberg HD, Shadomy HJ (eds) Manual of Clinical Microbiology. American Society for Microbiology, Washington, DC, 1991, pp. 128-136.
8. Sutter VL, Citron DM, Edelstein MAC, Finegold SM. Wadsworth Anaerobic Bacteriology Manual, 4th ed. Star Publishing Co., Belmont, CA, 1985.
9. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Antibacterial Susceptibility Testing of Anaerobic Bacteria, 3rd ed. M-11-A2. Villanova, PA, 1993.
10. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 3rd ed. M7-A2. Villanova, PA, 1993.
11. Jacobus NV, Labthavikul P, Spengler MD, Bradford PA, Bush K, Testa RT. Characterization of β-lactamases in three collections of E. coli and K. pneumoniae as related to susceptibility to Piperacillin/Tazobactam and other extended spectrum β-lactams. 95th General Meeting of the American Society for Microbiology. Abstract A73, Washington, DC, 1995.
12. Murray PR, Cantrell HF, Lankford RB, In Vitro Susceptibility Surveillance Group. Multicenter evaluation of in vitro activity of piperacillin-tazobactam compared with eleven selected β-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. Diagn Microbiol Inf Dis 1994;19:111-120.
13. Marshall SA, Aldridge KE, Allen SD, Fuchs PC, Gerlach EH, Jones RN. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. Diag Microbiol Inf Dis 1995;21:153-168.
14. Baron EJ, Jones RN. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diag Microbiol Inf Dis 1995;21:141-151.
15. Jones RN, Pfaller MA, Fuchs PC, Aldridge K, Allen SD, Gerlach EH. Piperacillin/tazobactam (YTR-830) combination: comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Inf Dis 1989;12:489-494.
16. Applebaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents including RP 59500, biapenem, trospectomycin, and piperacillin/tazobactam. J Antimicrob Chemother 1993;32:223-231.
17. Aldridge KE, Gelfand M, Reller LB, et al. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin and metronidazole in the United States. Diagn Microbiol Inf Dis 1994;18:235-241.
18. Grimm H. A multicenter in vitro evaluation of piperacillin/tazobactam in Germany. Eur J Surg 1994;(Suppl)573:25-29.
19. Acar JF, Goldstein FW, Kitzis MD. Susceptibility survey of piperacillin alone and in the presence of tazobactam. J Antimicrob Chemother 1993;31(Suppl A):23-28.
20. Chen HY, Bonfiglio G, Allen M, et al. Multicenter survey of the comparative in vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles. J Antimicrob Chemother 1993;32:247-266.
21. Investigators of the Piperacillin/Tazobactam Intraabdominal Infection Study Group. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intraabdominal infections. Eur J Surg 1994;Suppl 573:61-66.
22. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin/tazobactam versus imipenem-cilastatin for treatment of intraabdominal infections. Antimicrob Agents Chemother 1992;36:2766-2773.
23. Niinikoski J, Havia T, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intraabdominal infections. Surg, Gyn Obstet 1993;176:255-261.
24. Shlaes DM, Boughman R, Boylen CT, et al. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infections. J Antimicrob Chemother 1994;34:565-577.
25. Mouton Y, Leroy O, Beuscart C, et al. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993;3(Suppl A):87-95.
26. Tan JS, Wishnow RM, Tolan DA, Duncanson FP, Norden CW, The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Treatment of hospitalized patients with complicated skin and skin structure infections: double blind, randomized multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother 1993;37:1580-1586.